Olema Pharmaceuticals
OLMA
74 hedge funds and large institutions have $1.16B invested in Olema Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 16 closing their positions.
106% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 16
30% more funds holding
Funds holding: 57 → 74 (+17)
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
3.32% less ownership
Funds ownership: 91.05% → 87.73% (-3.3%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less capital invested
Capital invested by funds: $1.66B → $1.16B (-$499M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$32.9M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.25M |
| 5 |
D.E. Shaw & Co
New York
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.2M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$18.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$12.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.35M |
OLMA Hedge Fund Activity: Q1 2021 in Review
74 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2021, worth a combined $1.16B — down 30% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new OLMA positions and 16 closed out — a net gain of 17 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $32.9M. The largest seller was Deerfield Management, cutting an estimated $18.2M.
- 74 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2021, up from 57 in Q4 2020.
- Funds reported $1.16B of Olema Pharmaceuticals stock for Q1 2021, down 30% quarter-over-quarter.
- 33 funds opened new Olema Pharmaceuticals positions in Q1 2021 and 16 closed out, a net change of +17 holders.
- The largest Olema Pharmaceuticals buyer in Q1 2021 was BlackRock, an estimated $32.9M added.
- The largest Olema Pharmaceuticals seller in Q1 2021 was Deerfield Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q1 2021.